GlassScriptPhysician profile
Roy W Harris
NPI 1043218902
$19,686.59
in general payments reported to CMS, 2019-2025
50 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,543 · 2020: $727 · 2021: $1,610 · 2022: $3,620 · 2023: $7,964 · 2024: $2,783 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,025 · Food and Beverage: $4,504 · Travel and Lodging: $1,408 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,025.00 |
| Food and Beverage | $4,504.04 |
| Travel and Lodging | $1,408.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $10,450.36 | 2021-2025 | |
| Abbvie INC. | $1,547.49 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,246.08 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $926.50 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $612.66 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $551.62 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $447.12 | 2019-2022 | |
| Glaxosmithkline, LLC. | $359.91 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $306.40 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $272.53 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $256.47 | 2025 | Caplyta |
| Medtronic, INC. | $210.03 | 2024-2025 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $204.75 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $159.71 | 2024-2025 | Fanapt |
| Evoke Pharma, INC. | $133.36 | 2020-2025 | Gimoti |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.